Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IceCure Medical (ICCM) Cash & Current Investments (2020 - 2025)

IceCure Medical (ICCM) has disclosed Cash & Current Investments for 5 consecutive years, with $7.6 million as the latest value for Q4 2024.

  • On a quarterly basis, Cash & Current Investments fell 31.62% to $7.6 million in Q4 2024 year-over-year; TTM through Dec 2024 was $7.6 million, a 31.62% decrease, with the full-year FY2024 number at $7.6 million, down 31.62% from a year prior.
  • Cash & Current Investments was $7.6 million for Q4 2024 at IceCure Medical, down from $11.1 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $25.6 million in Q4 2021 to a low of $7.6 million in Q4 2024.
  • A 5-year average of $15.3 million and a median of $11.1 million in 2023 define the central range for Cash & Current Investments.
  • Peak YoY movement for Cash & Current Investments: skyrocketed 213.56% in 2021, then plummeted 53.82% in 2023.
  • IceCure Medical's Cash & Current Investments stood at $8.2 million in 2020, then surged by 213.56% to $25.6 million in 2021, then fell by 6.5% to $24.0 million in 2022, then tumbled by 53.82% to $11.1 million in 2023, then tumbled by 31.62% to $7.6 million in 2024.
  • Per Business Quant, the three most recent readings for ICCM's Cash & Current Investments are $7.6 million (Q4 2024), $11.1 million (Q4 2023), and $24.0 million (Q4 2022).